Human pluripotent stem cell-derived macrophages and macrophage-derived exosomes: therapeutic potential in pulmonary fibrosis

Stem Cell Res Ther. 2022 Sep 2;13(1):433. doi: 10.1186/s13287-022-03136-z.

Abstract

Pulmonary fibrosis (PF) is a fatal chronic disease characterized by accumulation of extracellular matrix and thickening of the alveolar wall, ultimately leading to respiratory failure. PF is thought to be initiated by the dysfunction and aberrant activation of a variety of cell types in the lung. In particular, several studies have demonstrated that macrophages play a pivotal role in the development and progression of PF through secretion of inflammatory cytokines, growth factors, and chemokines, suggesting that they could be an alternative therapeutic source as well as therapeutic target for PF. In this review, we describe the characteristics, functions, and origins of subsets of macrophages involved in PF and summarize current data on the generation and therapeutic application of macrophages derived from pluripotent stem cells for the treatment of fibrotic diseases. Additionally, we discuss the use of macrophage-derived exosomes to repair fibrotic lung tissue.

Keywords: Exosomes; IPF; Macrophages; Respiratory disease; hPSC.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Exosomes* / metabolism
  • Humans
  • Lung / pathology
  • Macrophages / metabolism
  • Pluripotent Stem Cells* / metabolism
  • Pulmonary Fibrosis* / metabolism
  • Pulmonary Fibrosis* / therapy